Rajesh Bandekar

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial

Frits van Rhee, Raymond Wong, Nikhil C. Munshi et al. · The Lancet Oncology · 2014 · 442 citations

Life Sciences, Immunology, Internal Medicine +5

A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Eric Angevin, Josep Tabernero, Elena Élez et al. · Clinical Cancer Research · 2014 · 206 citations

Pharmacy, Oncology, Pharmacology +17

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

Karim Fizazi, Johann S. de Bono, Aude Fléchon et al. · European Journal of Cancer · 2011 · 195 citations

Medicine, Oncology, Pharmacotherapy +17

A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

Robert Z. Orlowski, Liana Gercheva, Cathy Williams et al. · American Journal of Hematology · 2014 · 132 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort

Matthew R. Smith, Emmanuel S. Antonarakis, Charles J. Ryan et al. · European Urology · 2016 · 126 citations · Full text

Medicine, Oncology, Pharmacology +17